Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Ent and Allergy

Neither a doctor nor a teaching hospital

Research payments

$562,424

95 payments

Through program year 2025, Advanced Ent and Allergy is reported as receiving $562,424 in research payments, across 95 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$38,410	8
2024	Research	$37,025	8
2023	Research	$48,096	12
2022	Research	$80,654	21
2021	Research	$155,330	19
2020	Research	$107,308	11
2019	Research	$95,601	16

Breakdown

Who paid Research payments · program years 2019–2025

Aerin Medical Inc. $204,398 37 payments
Otonomy, Inc. $83,628 8 payments
Sanofi US Services Inc. $81,502 11 payments
Intersect ENT, Inc. $79,953 17 payments
Genzyme Corporation $58,057 17 payments
Hill Dermaceuticals, Inc. $49,235 2 payments
Medtronic, Inc. $5,650 3 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus $80,412 5 payments
CTP 1056 - Relief $69,076 14 payments
CTP 1006 - Vatrac $59,741 13 payments
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients $58,057 17 payments
TP668 - PNN Pivotal $48,687 4 payments
Ascend $42,438 7 payments
Expand $40,905 10 payments
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) $40,786 4 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps $34,636 6 payments
Tp668 Rhinitis PNN $26,895 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.